Bradbury R H, Rivett J E
Department of Chemistry, ICI Pharmaceuticals, Macclesfield, Cheshire, U.K.
J Med Chem. 1991 Jan;34(1):151-7. doi: 10.1021/jm00105a022.
Two series of 1,2,4-triazolo[4,3-a]pyrazine derivatives with human renin inhibitory activity have been synthesized which incorporate the transition-state mimetics (3S,4S)- and (3R,4S)-5-cyclohexyl-3,4-diaminopentanoic acid ((S)- and (R)-CDAPA), and (4S)-4-amino-5-cyclohexyl-2,2-difluoro-3-oxopentanoic acid (ACDFOPA). Several compounds in these series, for example 13a, 19c, and 19f, were highly potent inhibitors of partially purified human renin (IC50 values of 3.9, 1.6, and 1.4 nM, respectively). The ACDFOPA-based compounds 19c and 19f contain no natural amino acid fragments and have molecular weights which compare well with those of previously reported inhibitors of nanomolar in vitro potency. When administered intravenously to anesthetized, sodium-depleted marmosets at doses of 3 mg/kg, compounds 13a and 19c caused a marked reduction in mean arterial pressure, but in the same animal model at 30 mg/kg, oral activity was not seen.
已合成了具有人肾素抑制活性的两系列1,2,4 - 三唑并[4,3 - a]吡嗪衍生物,它们包含过渡态模拟物(3S,4S)-和(3R,4S)-5 - 环己基 - 3,4 - 二氨基戊酸((S)-和(R)-CDAPA),以及(4S)-4 - 氨基 - 5 - 环己基 - 2,2 - 二氟 - 3 - 氧代戊酸(ACDFOPA)。这些系列中的几种化合物,例如13a、19c和19f,是部分纯化的人肾素的高效抑制剂(IC50值分别为3.9、1.6和1.4 nM)。基于ACDFOPA的化合物19c和19f不含天然氨基酸片段,其分子量与先前报道的具有纳摩尔体外效力的抑制剂相当。当以3 mg/kg的剂量静脉注射给麻醉的、缺钠的狨猴时,化合物13a和19c导致平均动脉压显著降低,但在相同动物模型中以30 mg/kg口服给药时,未观察到口服活性。